130 related articles for article (PubMed ID: 25329832)
21. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
[TBL] [Abstract][Full Text] [Related]
22. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies.
He B; Mai Q; Pang Y; Deng S; He Y; Xue R; Xu N; Zhou H; Liu X; Xuan L; Li C; Liu Q
Front Immunol; 2023; 14():1130442. PubMed ID: 37207215
[TBL] [Abstract][Full Text] [Related]
23. The Notch signaling pathway: a potential target for cancer immunotherapy.
Li X; Yan X; Wang Y; Kaur B; Han H; Yu J
J Hematol Oncol; 2023 May; 16(1):45. PubMed ID: 37131214
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic virotherapy: basic principles, recent advances and future directions.
Lin D; Shen Y; Liang T
Signal Transduct Target Ther; 2023 Apr; 8(1):156. PubMed ID: 37041165
[TBL] [Abstract][Full Text] [Related]
25. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
26. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
27. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].
Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV
Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385
[TBL] [Abstract][Full Text] [Related]
28. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic
Yeşilaltay A; Muz D; Erdal B
Turk J Haematol; 2024 Mar; 41(1):16-25. PubMed ID: 38258554
[TBL] [Abstract][Full Text] [Related]
30. Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma.
Yeşilaltay A; Muz D; Erdal B; Bilgen T; Batar B; Turgut B; Topçu B; Yılmaz B; Avcı BA
Pathogens; 2024 Jan; 13(1):. PubMed ID: 38251379
[TBL] [Abstract][Full Text] [Related]
31. Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma.
Ashton LV; Weishaar KM; Séguin B; MacNeill AL
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760788
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response.
Shakiba Y; Vorobyev PO; Yusubalieva GM; Kochetkov DV; Zajtseva KV; Valikhov MP; Kalsin VA; Zabozlaev FG; Semkina AS; Troitskiy AV; Baklaushev VP; Chumakov PM; Lipatova AV
Mol Ther Oncolytics; 2023 Jun; 29():158-168. PubMed ID: 37387795
[TBL] [Abstract][Full Text] [Related]
33. Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer.
Rahman MM; van Oosterom F; Enow JA; Hossain M; Gutierrez-Jensen AD; Cashen M; Everts A; Lowe K; Kilbourne J; Daggett-Vondras J; Karr TL; McFadden G
Cancer Res Commun; 2023 Jun; 3(6):952-968. PubMed ID: 37377603
[TBL] [Abstract][Full Text] [Related]
34. Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity.
Mendoza-Valderrey A; Alvarez M; De Maria A; Margolin K; Melero I; Ascierto ML
Cells; 2022 Oct; 11(19):. PubMed ID: 36231109
[TBL] [Abstract][Full Text] [Related]
35. Current Progress of CAR-NK Therapy in Cancer Treatment.
Pang Z; Wang Z; Li F; Feng C; Mu X
Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077853
[TBL] [Abstract][Full Text] [Related]
36. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.
Mardi A; Shirokova AV; Mohammed RN; Keshavarz A; Zekiy AO; Thangavelu L; Mohamad TAM; Marofi F; Shomali N; Zamani A; Akbari M
Cancer Cell Int; 2022 Apr; 22(1):168. PubMed ID: 35488303
[TBL] [Abstract][Full Text] [Related]
37. The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.
Warricker F; Khakoo SI; Blunt MD
J Transl Genet Genom; 2021; 5():304-322. PubMed ID: 34888493
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of interleukin-15 in cancer (Review).
Isvoranu G; Surcel M; Munteanu AN; Bratu OG; Ionita-Radu F; Neagu MT; Chiritoiu-Butnaru M
Exp Ther Med; 2021 Jul; 22(1):675. PubMed ID: 33986840
[TBL] [Abstract][Full Text] [Related]
39. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
Zhang S; Rabkin SD
Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
[No Abstract] [Full Text] [Related]
40. Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
Torres-Domínguez LE; de Matos AL; Rahman MM; McFadden G
Methods Mol Biol; 2021; 2225():63-75. PubMed ID: 33108657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
